Argonne National Laboratory

Users Week 2007
May 7-12, 2007

Argonne Home > Argonne Home > Advanced Photon Source >

Registration & Abstracts
Practical Matters

- April 9: poster abstracts
- April 10: non-U.S. registration
- April 22: housing
- April 23: registration


Download Poster
- 8.5 x 11
- 11 x 17

For Organizers


Past Meetings


Workshop 5

Wednesday, May 9
Guest House
9:00 - 12:00
1:00 - 4:45

WK5 - Drug Discovery at the Advanced Photon Source

Barry Finzel, Pfizer
Bill Stallings, ProXyChem

To agenda > (updated 4/16/07)


The past decade has seen significant advances in the ability of single crystal x-ray diffraction experiments to impact the drug discovery process.  The development and implementation of high energy synchrotron radiation sources, fast detector technologies, and robotic automation have enabled an unprecedented number of crystals to be evaluated in the accelerated timeline demanded by the industrial drug development process.  Using x-ray crystallography, atomic resolution structures of drugs bound to their target proteins can be obtained that provide invaluable information related to how these compounds physically interact with their target.  In many cases, this information can suggest ways to improve binding properties, modulate physicochemical properties of the compound without impacting binding affinity, and facilitate the design of novel compounds using computational techniques.  This workshop will discuss real-life examples of how crystal structures determined using APS facilities have impacted drug discovery.  Topics will also include the technical capabilities of APS beamlines and the role of structural genomics in modern drug discovery.


9:00 - 9:30

Structure-Based Drug Discovery: Past, Present and Future Perspectives
Cele Abad-Zapatero, University of Illinois at Chicago

9:30 - 10:00

Fragment-based Discovery of Selective, Orally Bioavailable Tyrosine Kinase Inhibitors for Targeted Treatment of Human Cancers
Steven Burley, SGX Pharmaceuticals

10:00 - 10:30

SGX-CAT: An Automated Synchrotron Beamline Dedicated to Mail-in Crystallography
Kevin D'Amico, SGX-CAT

10:30 - 11:00


11:00 - 11:30

IMCA-CAT:  A Research Facility for Pharmaceutical Drug Discovery
Lisa Keefe, IMCA-CAT 

11:30 - 12:00

Tykerb: A Dual EGFR/ErbB2 Inhibitor
Lisa Shewchuk, GlaxoSmithKline

12:00 - 1:00


1:00 - 1:30

Structure-assisted Vaccine Design of the b12 Epitope on HIV-1 gp120
Tongqing Zhou, NIH

1:30 - 2:00

High-throughput Crystallography for Drug Discovery in Practice
Gyogy Snell, Takeda 

2:00 - 2:30

Recent Progress in the Structural Biology of Translation
Frank Murphy, NE-CAT 

2:30 - 3:00


3:00 - 3:45

Structural Studies of Two Potential Drug Targets for Treating Cardiovascular Diseases
Xiayang Qiu, Pfizer

3:45 - 4:15

Structural Insights for DPP-IV Inhibition
Kenton Longenecker, Abbott Laboratories

4:15 - 4:45

From HTS to Lead: How Structural Chemistry Shaped Anti-HCV Lead Selection
Barry Finzel, Pfizer 


U.S. Department of Energy UChicago Argonne LLC Office of Science - Department of Energy
Privacy & Security Notice | Contact Us | Site Map